ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,262.39
-0.57%
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs Yen
157.503
0.06%
Brent Oil
81.865
-0.32%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Tenax Therapeutics Inc (TENX)

  7. Tenax Therapeutics Inc (TENX) ニュース

TENX

Tenax Therapeutics (TENX)

Tenax Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:TENX
日付受信時刻ニュースソース見出しコード企業名
2024/06/1405 : 32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
2024/05/2505 : 31Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:TENXTenax Therapeutics Inc
2024/05/2206 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TENXTenax Therapeutics Inc
2024/05/2206 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TENXTenax Therapeutics Inc
2024/05/1505 : 01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TENXTenax Therapeutics Inc
2024/05/1422 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
2024/05/1421 : 00GlobeNewswire Inc.Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:TENXTenax Therapeutics Inc
2024/04/3020 : 30GlobeNewswire Inc.Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
2024/04/0921 : 30GlobeNewswire Inc.Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”NASDAQ:TENXTenax Therapeutics Inc
2024/03/2821 : 30GlobeNewswire Inc.Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ResultsNASDAQ:TENXTenax Therapeutics Inc
2024/03/1221 : 30GlobeNewswire Inc.Tenax Therapeutics to Present at the 36th Annual Roth ConferenceNASDAQ:TENXTenax Therapeutics Inc
2024/02/2923 : 00GlobeNewswire Inc.Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024NASDAQ:TENXTenax Therapeutics Inc
2024/02/2706 : 31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
2024/02/2706 : 31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
2024/02/2406 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
2024/02/2206 : 32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
2024/02/2206 : 30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
2024/02/2106 : 01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
2024/02/2022 : 33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
2024/02/2022 : 30GlobeNewswire Inc.Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to LevosimendanNASDAQ:TENXTenax Therapeutics Inc
2024/02/1701 : 28Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
2024/02/1609 : 36Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
2024/02/1504 : 58Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TENXTenax Therapeutics Inc
2024/02/1406 : 32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
2024/02/1306 : 46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
2024/02/1007 : 00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:TENXTenax Therapeutics Inc
2024/02/0906 : 51Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
2024/02/0822 : 16GlobeNewswire Inc.Tenax Therapeutics Announces Pricing of Approximately $9 Million Public OfferingNASDAQ:TENXTenax Therapeutics Inc
2024/02/0814 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TENXTenax Therapeutics Inc
2024/02/0810 : 01GlobeNewswire Inc.Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TENX

最近閲覧した銘柄

AMEX
XLE
Energy Select Sector SPDR
CCOM
SILVER
SILVER
NASDAQ
TSLA
Tesla
FX
USDJPY
US Dollar vs Yen
NYSE
XOM
Exxon Mobil
AMEX
XLV
Health Care Select Sector
AMEX
XLF
Financial Select Sector
USOTC
BASFY
BASF (QX)
NYSE
NKE
Nike
CCOM
US100
US Tech 100
SPI
SP500
S&P 500
FX
USDEUR
US Dollar vs Euro
NASDAQ
NVDA
NVIDIA
NASDAQ
GOOGL
Alphabet
NYSE
CVX
Chevron
USOTC
BNPQY
BNP Paribas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有